Key Highlights

  • CVS Caremark reinstates Zepbound (tirzepatide) as a preferred GLP-1 option from October 1, 2026
  • Foundayo, Eli Lilly's oral obesity therapy, gains formulary coverage effective June 1, 2026
  • Eli Lilly and Novo Nordisk reach co-preferred status on plans covering 25–30 million Americans
  • CVS projects 10–15% additional savings in the weight management category following these changes
  • All three major pharmacy benefit managers will now cover Lilly's oral GLP-1 therapy

CVS Health (NYSE:CVS) announced on Thursday that its pharmacy benefits arm, CVS Caremark, will expand coverage of GLP-1 weight management therapies by reinstating Eli Lilly's (NYSE:LLY) Zepbound injection and adding Foundayo, the company's newly approved oral obesity pill. The announcement marks a significant strategic reset from 2025, when CVS struck an exclusive arrangement that installed Novo Nordisk's (NYSE:NVO) Wegovy as the sole preferred weight loss option across its standard commercial formularies.

From exclusivity to co-preference

Last year's Wegovy deal was a deliberate market intervention: concentrating patient Volume on a single manufacturer to extract deeper pricing concessions. CVS now argues that strategy succeeded. The price pressure it generated was sufficient to bring Eli Lilly to the table, and the result is a more competitive formulary structure, with both both Zepbound and Wegovy hold preferred status simultaneously.

Zepbound will be reinstated as a preferred option on October 1, 2026. Foundayo, which uses the active compound orforglipron and is administered orally rather than by injection, will be covered from June 1, 2026. Novo Nordisk retains its preferred position; its injectable and oral Wegovy formulations remain on the formulary without disruption to existing patients.

The combined template covers an estimated 25 to 30 million Americans. However, plan sponsors including employers, unions, and health plans that contract with Caremark retain the right to exclude GLP-1 weight management coverage altogether. Expanded formulary Options do not automatically translate into expanded patient access.

Affordability and the limits of competition

High list prices remain the structural constraint in this market. GLP-1 therapies have generated substantial clinical Demand, but the cost burden has led many plan sponsors to either limit coverage or exclude it entirely. CVS frames its formulary strategy as the mechanism that produced the cost reductions now enabling broader access, pointing to consistent double-digit savings for template formulary customers in prior years. The company projects a further 10 to 15 percentage point reduction in category spending under the updated structure.

Whether those savings are shared meaningfully with patients depends on decisions made at the plan level, well beyond CVS Caremark's direct control. The structural tension between high manufacturer pricing and sustainable benefit design has not been resolved; it has been modestly eased.

The oral GLP-1 dimension

The inclusion of Foundayo carries significance beyond the competitive balance between Lilly and Novo Nordisk. Oral GLP-1 medications remove the barrier of injectable administration, broadening the population for whom treatment is practically viable. Lilly confirmed that Foundayo will be covered across all three of the country's largest pharmacy benefit managers, suggesting a commercial launch velocity that few novel branded therapies achieve.

Oral and injectable formulations will increasingly compete for preferred tier Placement in future formulary cycles, providing benefit managers additional negotiating Leverage. That competitive dynamic, in principle, supports continued downward pressure on GLP-1 pricing, though the pace depends on what clinical differentiation each manufacturer can credibly sustain.